文献速递前列腺癌

前列腺癌「nimbosus」:基因组不稳定与SChLAP1失调 underpins 导管内和筛状亚型的侵袭性

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
PubMed 文献 · Eur Urol · 2017-05-13

研究纳入4家学术机构的1325例局限性前列腺癌患者,集中复核病理并检测基因拷贝数、表达及前列腺内氧合。导管内癌/筛状结构(IDC/CA)独立预测生化复发(加拿大队列HR 2.17,p<0.001;MSKCC队列HR 2.32,p=0.0035)和转移(汇总HR 3.31,p<0.001)。IDC/CA+肿瘤基因组改变百分比中位数7.2 vs 3.0(p<0.001),缺氧比例64.0% vs 45.5%(p=0.17),SChLAP1表达升高>3倍(p<0.0001)。

要点

  • IDC/CA独立预测生化复发和转移风险升高。
  • IDC/CA+肿瘤基因组改变百分比更高,SChLAP1表达升高。
  • 基因组-病理联合指标对转移的区分度优于临床指标。

核心结论

  • IDC和CA亚型的不良结局与基因组不稳定、SChLAP1表达和缺氧等一系列特征相关。
  • 作者提出IDC/CA+前列腺癌的新概念「nimbosus」,表现为转移能力和致死性增加。
  • IDC/CA+前列腺癌的最佳治疗强化需要前瞻性试验验证。

研究设计与样本

  • 研究纳入4家学术机构(University Health Network、CHU de Québec-Université Laval、Memorial Sloan Kettering Cancer Center、Erasmus Medical Center)的1325例局限性前列腺癌患者。
  • 病理标本经集中复核,评估基因拷贝数和表达以及前列腺内氧合。
  • 在加拿大队列和MSKCC队列中分别评估IDC/CA的生化复发风险,两队列汇总分析转移。

主要发现

  • IDC/CA独立预测生化复发风险升高(加拿大队列HR 2.17,p<0.001;MSKCC队列HR 2.32,p=0.0035)。
  • IDC/CA独立预测转移风险升高(汇总HR 3.31,p<0.001)。
  • IDC/CA+肿瘤基因组改变百分比中位数7.2 vs IDC/CA- 3.0(p<0.001)。
  • IDC/CA+肿瘤缺氧比例64.0% vs IDC/CA- 45.5%(p=0.17)。
  • SChLAP1在IDC/CA+肿瘤中表达较IDC/CA-升高>3倍(p<0.0001),原位杂交信号增加。

关键数值与推荐

  • 转移区分度C-index:临床+IDC/CA+PGA 0.805 vs 临床+IDC/CA 0.786 vs 临床 0.761。

临床怎么用

  • 作者认为,对于IDC/CA+前列腺癌这一不良亚组,应考虑现代影像用于监测以及治疗强化试验。

局限性

  • IDC/CA+前列腺癌的最佳治疗强化需要前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. OBJECTIVE: We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. DESIGN, SETTING, AND PARTICIPANTS: A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis. RESULTS AND LIMITATION: Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing. CONCLUSIONS: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality. PATIENT SUMMARY: A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chua MLK, Lo W, Pintilie M, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol. 2017. PMID: 28511883. doi:10.1016/j.eururo.2017.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。